Cerebrolysin

Cerebrolysin

Information

Cerebrolysin is an injectable mix of small peptides and free amino acids derived from pig brain tissue. The fragments are small enough to cross the blood-brain barrier, where they act like the brain's own growth factors (BDNF, NGF, GDNF). It's the most clinically validated neurotrophic peptide available, with 200+ trials behind it across stroke, TBI, and dementia. Used extensively in russia and eastern europe for stroke recovery
In the biohacker world it's used as a high-end nootropic and brain repair tool. People run it for sharper memory and verbal recall, faster mental processing, recovery from concussion or long COVID brain fog, and as a long-game protective stack for cognitive aging. Effects build over a 10 to 20 day cycle and tend to persist for months after stopping. It's injected, not oral, which puts it in a different tier from your standard nootropic shelf.
Deep-dive

What's actually in it

Cerebrolysin is roughly 75% free amino acids and 25% low-molecular-weight peptides (under 10 kDa). Peptide analysis has identified active fragments resembling nerve growth factor, enkephalins, orexin, and galanin. The peptide fraction drives the neurotrophic effects, the amino acids contribute substrate.

How it works

Cerebrolysin is pleiotropic, meaning it acts on several pathways at once rather than hitting a single receptor. This is why it has a use case in conditions where single-target drugs have failed.
It mimics endogenous neurotrophic factors. Full-sized BDNF, NGF, and GDNF can't cross the blood-brain barrier, but Cerebrolysin's small fragments can, and they activate the same downstream signaling. An in vitro study showed it directly upregulates BDNF expression in neural cells. BDNF is the "fertilizer" for synaptic plasticity, the molecule responsible for memory consolidation and learning.
It modulates the PI3K/Akt and Sonic hedgehog pathways, which protect neurons from apoptosis and support blood-brain barrier integrity. It inhibits calpain, the enzyme that breaks down structural proteins inside neurons under stress. And it actively induces neurogenesis and neuronal sprouting, which is the key piece for the nootropic angle: you're not just protecting what's there, you're growing new connections.

What the clinical evidence shows

Stroke recovery is the most studied use. The CARS trial showed Cerebrolysin started 24 to 72 hours after ischemic stroke produced better motor recovery at day 90. A 2025 meta-analysis of 14 RCTs covering 2,884 patients found significant improvements in NIHSS scores with no increase in serious adverse events. Effect size grows with stroke severity.
Traumatic brain injury. The CAPTAIN trial series in moderate-to-severe TBI showed improved outcomes at 10, 30, and 90 days post-injury. A retrospective multi-center cohort showed dose-dependent benefit across mild, moderate, and severe cases. This is the most relevant data for anyone using it after concussion or head impacts.
Alzheimer's and vascular dementia. A meta-analysis of mild-to-moderate Alzheimer's trials found significant improvements in cognitive function and global clinical change at 4 weeks and 6 months. Effects are most pronounced when combined with cholinesterase inhibitors.
For healthy nootropic users, formal RCT data is thin, the trials haven't been run. But the mechanism (BDNF upregulation, neurogenesis, synaptic plasticity) is exactly what nootropic users want, and subjective reports are remarkably consistent: cleaner mental processing, better word recall, sharper focus, mood lift. The effect is not a stimulant rush, it builds across a cycle and stays for weeks to months after.

Limitations of the evidence

Most positive trials are sponsored by EVER Neuro Pharma, the manufacturer. Earlier Cochrane reviews concluded the evidence was insufficient for stroke or vascular dementia, more recent meta-analyses with larger samples have been more favorable. There's heterogeneity in dosing, timing, and patient populations across trials.
A 2020 study suggested no benefit in hemorrhagic stroke from cerebral aneurysm. In milder strokes the effect is harder to detect because outcomes are already good.

For women

Cerebrolysin trials have included roughly equal numbers of men and women, particularly the dementia and stroke trials where women are often the majority. Subgroup analyses in CARS stratified by sex and found consistent results, women respond comparably to men. A preclinical dose-response study explicitly looked for treatment-by-sex interactions in stroke models and found none.
This matters because women have higher lifetime risk of both stroke and Alzheimer's, and post-stroke recovery in women tends to be worse than in men. The case for using Cerebrolysin in women is at least as strong as in men. For pregnancy and breastfeeding there's no human safety data, so don't use it.

For older adults

This is the population with the most direct evidence. Almost all Alzheimer's, vascular dementia, and stroke trials enrolled adults over 50, often over 65. Tolerability is good across these age groups. The combination with cholinesterase inhibitors (donepezil, rivastigmine) extends and enhances the effect of those drugs in moderate-to-advanced Alzheimer's, per this 30-year clinical use review.

Dosage

Cerebrolysin is injected, intramuscularly (IM) for smaller volumes or intravenously (IV) for larger ones. It's sold in 1, 2, 5, 10, and 20 ml ampoules at a standardized concentration of 215.2 mg/ml.
  • Standard nootropic / cognitive enhancement cycle: 5 ml IM daily for 10 to 20 days, then off. This is the most common biohacker protocol, accessible because IM doesn't require IV equipment.
  • Aggressive nootropic / mild cognitive support: 10 ml IM or IV daily for 10 to 20 days. Some users split this as 5 ml twice daily.
  • Recovery from concussion, post-concussion syndrome, or brain fog: 10 to 20 ml IV daily, diluted in 100 ml saline, for 10 to 20 days. Start as soon as practical after injury.
  • Early cognitive decline / MCI: 10 to 20 ml IV daily, 10 to 20 day cycles, repeat every 3 to 6 months.
  • Acute ischemic stroke (clinical setting): 30 ml IV daily for 10 to 21 days, started within 24 to 72 hours, paired with rehab. The CARS protocol.
  • Moderate-to-severe TBI (clinical setting): 50 ml IV daily for 10 days, then 10 ml daily for two further 10-day cycles. The CAPTAIN protocol.
For all uses: IM injections of up to 5 ml can be given undiluted, slowly over about 3 minutes. Volumes above 5 ml should be diluted in saline and given IV over at least 15 minutes. Cycle, don't run continuously, most protocols are 10 to 20 days on, then weeks to months off before the next round. Morning dosing is standard to align with circadian rhythms and avoid sleep disruption from the mild stimulating effect.
Women and men use the same dosing. There are no documented sex-based pharmacokinetic differences. Older adults tolerate the same doses as younger adults in trials.

Here's what you can expect

For nootropic use, expect cleaner mental processing, better verbal recall and word retrieval, and a sustained focus boost that builds across the first week of a cycle. Many users report a noticeable mood lift, particularly under stress. The effect is smooth and "underneath" rather than a rush, you notice it most when you're working and realize the friction has dropped. Most people feel the effect peaking around days 7 to 14 of a cycle, and benefits often persist for 1 to 3 months after the last injection because the underlying neurogenesis and synaptic changes don't reverse immediately.
For post-concussion or brain fog recovery, expect clearer thinking, reduced mental fatigue, and faster recovery of verbal fluency and short-term memory across a 10 to 20 day cycle. Some users report this is where Cerebrolysin shines most.
For dementia and cognitive decline, expect modest improvements in cognitive scores and clinician-rated function, particularly within the first 4 weeks of a course. Effects persist for weeks to months, which is why repeat cycles every 3 to 6 months are standard.
For acute stroke or TBI in clinical settings, expect measurable improvements in motor function and global recovery over the first 30 to 90 days, clearest in moderate-to-severe cases.

Side effects & risks

The safety profile is excellent. A meta-analysis of 12 stroke RCTs covering 2,202 patients found no significant difference in adverse events, serious adverse events, or mortality versus placebo. The highest dose (50 ml) actually showed a moderate reduction in serious adverse events.
Common, mild, transient: vertigo, dizziness, headache, mild nausea, sweating, feeling hot, agitation, injection site reactions (warmth, redness, mild pain at the IM site). These usually resolve within hours of injection or after the first few doses.
Less common: elevated blood pressure, palpitations, restlessness. Worth monitoring if you have pre-existing hypertension. Some users report mild insomnia if they inject too late in the day, which is why morning dosing is standard.
Rare: hypersensitivity reactions. The product is porcine-derived, so anyone with a known pig protein allergy shouldn't use it. A small test dose on first administration is sensible.
Don't use if:
  • You have epilepsy or a history of seizures. Cerebrolysin can lower seizure threshold and increase seizure frequency, particularly grand mal.
  • You have severe or acute kidney failure. Peptide-based drugs place load on the kidneys.
  • You're pregnant or breastfeeding. No human safety data.
  • You have a known porcine protein allergy.
Interactions: Generally minimal. Caution with MAO inhibitors due to theoretical risk of additive central effects. There's evidence Cerebrolysin can increase brain accumulation of lithium, monitor closely if combined. It's been shown safe alongside cholinesterase inhibitors (donepezil, rivastigmine) and tPA. Stacking with other peptides like Semax or Selank is common in biohacker protocols and well tolerated.
🩸 Blood markers
Cerebrolysin is mostly notable for what it doesn't disturb. Across multi-week trials, vital signs and labs (hematology, liver, kidney) didn't show meaningful changes versus placebo.
At baseline: Run a basic metabolic panel including creatinine and eGFR. Severe renal impairment is a hard contraindication and you want a clear baseline before any peptide therapy. CBC and liver panel (AST, ALT) are reasonable additions to establish your normal range. Have blood pressure on file and well-controlled.
When to recheck: For a single short cycle (10 to 20 days) in an otherwise healthy adult, no recheck needed unless symptoms develop. For repeated cycles, particularly in older adults or anyone with borderline kidney function, recheck creatinine and eGFR every 3 months or after each course. Monitor blood pressure during cycles if you have hypertension.
Who actually needs what: Healthy adults running a single nootropic cycle realistically need a baseline metabolic panel and that's it. Older adults, anyone with kidney concerns, anyone running back-to-back cycles, or anyone combining with other neuroactive drugs (lithium, cholinesterase inhibitors, antiepileptics) should monitor more closely.
Cerebrolysin is prescription-only in countries where it's approved (most of Europe, Asia, the former Soviet states). Not approved in the US. Use injectable peptides under appropriate medical supervision.